[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100574258":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":29,"locations":25,"responsibleParty":35,"collaborators":25,"id":37,"slug":38,"hasResults":39,"nctId":40,"briefTitle":41,"officialTitle":41,"acronym":42,"eligibilityCriteria":43,"healthyVolunteers":39,"sex":44,"minAge":45,"maxAge":25,"enrollmentInfo":46,"targetDuration":25,"studyType":49,"phases":50,"briefSummary":52,"conditions":53,"keywords":25,"overallStatus":55,"whyStopped":25,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":25},{"fullName":5,"class":6},"Beijing Anzhen Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Aspirin 50mg\u002Fd","EXPERIMENTAL","STEMI patients receive aspirin 50 mg once daily (one 50 mg aspirin tablet plus one matching placebo tablet) plus ticagrelor 90 mg twice daily",[13],"Drug: aspirin 50 mg once daily (one 50 mg aspirin tablet plus one matching placebo tablet) plus ticagrelor 90 mg twice daily",{"label":15,"type":16,"description":17,"interventionNames":18},"Aspirin 100mg\u002Fd","ACTIVE_COMPARATOR","STEMI patients receive aspirin 100 mg once daily (two 50 mg aspirin tablets) plus ticagrelor 90 mg twice daily",[19],"Drug: aspirin 100 mg once daily (two 50 mg aspirin tablets) plus ticagrelor 90 mg twice daily",[21,26],{"type":22,"name":23,"description":11,"armGroupLabels":24,"otherNames":25},"DRUG","aspirin 50 mg once daily (one 50 mg aspirin tablet plus one matching placebo tablet) plus ticagrelor 90 mg twice daily",[9],null,{"type":22,"name":27,"description":17,"armGroupLabels":28,"otherNames":25},"aspirin 100 mg once daily (two 50 mg aspirin tablets) plus ticagrelor 90 mg twice daily",[15],[30],{"name":31,"role":32,"phone":33,"phoneExt":25,"email":34},"Wen Zheng, doctor","CONTACT","86+18611384411","mosquito99@126.com",{"type":36,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100574258","phase-4-low-dose-evaluation-of-aspirin-after-stemi-patients-with-pci-a-multicenter-double-blind-randomized-controlled-clinical-trial-100574258",false,"NCT06756945","Low-dose Evaluation of Aspirin After STEMI Patients With PCI: A Multicenter, Double-blind, Randomized Controlled Clinical Trial","LEAST","Inclusion Criteria:\n\nSTEMI patients with clear diagnosis Has received PCI treatment (at least the culprit's blood vessels have been treated); 18 years old and above, regardless of gender; Received DAPT upon discharge: aspirin+ticagrelor; Signed informed consent form approved by the ethics committee\n\nExclusion Criteria:\n\nIndividuals with atrial fibrillation\u002FDVT\u002Fvalve surgery requiring anticoagulant medication; Combined cardiomyopathy (HCM\u002FDCM\u002FRCM); Combining severe ventricular arrhythmias requires ICD; Chronic obstructive pulmonary disease (bronchial asthma, chronic bronchitis, emphysema, pulmonary heart disease); Serious infectious diseases, including active hepatitis B, hepatitis C or AIDS patients; Diseases of the blood system, such as thrombocytopenia, severe anemia, leukemia, etc; Severe liver and kidney dysfunction; Malignant tumors; Cognitive impairment","ALL","18 Years",{"count":47,"type":48},3612,"ESTIMATED","INTERVENTIONAL",[51],"PHASE4","The study aims to optimize the dual antiplatelet therapy regimen for patients with STEMI after PCI, focusing on addressing the following key technical challenges: establishing an effectiveness evaluation system for a low-dose aspirin (50mg\u002Fday) antithrombotic treatment strategy based on ticagrelor, including the formulation of a scientific non-inferiority margin, assessment criteria, and composite endpoint determination standards; constructing a strict risk assessment system for major bleeding events, including bleeding event grading based on BARC standards and a blind evaluation process by an independent endpoint event adjudication committee; and developing a quality control system for multicenter clinical research to ensure patient follow-up compliance and data reliability. By solving the above technical challenges, the study provides evidence-based medical support and technical support for optimizing the antithrombotic treatment regimen for STEMI patients after PCI.",[54],"ST-elevation Myocardial Infarction (STEMI)","NOT_YET_RECRUITING","2024-12-24",{"date":58,"type":59},"2025-01-03","ACTUAL",{"date":61,"type":48},"2025-01",{"date":63,"type":48},"2027-12",{"name":5,"class":6}]